ASMB
Assembly Biosciences, Inc. Health Care Pharmaceutical Preparations Russell 3000
$20.13Close
$319.2MMarket cap
$19.67 – $38.5052-week range
Nov 9, 2026Next report
Highlights
Strengths
- Volume drying up last 10 days 39% under the 50-day average
Cautions
- Not in an uptrend 0 of 8 trend conditions
- Lagging the market RS 11 · weaker than 89% of stocks over 12 months
- Far from its high 48% below its 52-week high
- Distribution down-day volume 1.6× up-day volume over 50 sessions
- Results soon Nov 9, 2026, in 8 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
48%
1wk
up 1.5%
price change
1mo
down 14.3%
price change
12-month return
down 33%
market up 11% ·
its own down 46%
F-score
—
— Not assessed
Altman Z
0.33
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
1.5×
price / book
Earnings yield
down 4.6%
EBIT / enterprise value
Cheaper than
33%
of the market · expensive
Revenue growth
up 154%
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 5%
return on equity
Free cash margin
down 57%
-$41.2M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
5.4%
$1.08 a day · 2×ATR $17.97
RS
11 / 99
vs the universe
Trend
0 / 8
trend template
Relative volume
0.5×
vs 50-day average
Up/down volume
0.63
50 sessions
Implied move
—
no option chain · report Nov 9, 2026
Contractions
3
41% → 16% → 12%
Pivot
$21.93
8.2% below
Volume dry-up
0.6×
10 vs 50 sessions
Trend template · 0 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 112.6% over the year, from 7m to 16m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
May 7, 2026
Financials
- Net -8%
- Free cash -57%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $79.1M | $6.3M | $0 | $7.2M | $28.5M | $72.3M |
| Operating income | -$64.8M | -$132.7M | -$94.1M | -$64.6M | -$45.4M | -$12.1M |
| Net income | -$62.2M | -$129.9M | -$93.1M | -$61.2M | -$40.2M | -$6.1M |
| Net margin | -79% | -2076% | — | -855% | -141% | -8% |
| Earnings per share | — | -$36.02 | -$23.08 | -$13.38 | -$6.69 | -$0.55 |
| Free cash flow | -$63.4M | -$96.5M | -$84.6M | $22.5M | -$51.1M | -$41.2M |
| Free cash margin | -80% | -1543% | — | 314% | -179% | -57% |
| Cash | $59.4M | $45.6M | $52.4M | $19.8M | $38.3M | $58.5M |
| Shareholders' equity | $240.6M | $168.9M | $82.7M | $41.1M | $33.4M | $206.8M |
| Shares outstanding | 2.83m | 4.01m | 4.07m | 5.48m | 7.46m | 15.86m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 13, 2026 | Quarterly ↗ | Jun 30, 2026 | 44d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Mar 19, 2026 | Annual ↗ | Dec 31, 2025 | 78d |
| Nov 10, 2025 | Quarterly ↗ | Sep 30, 2025 | 41d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Mar 20, 2025 | Annual ↗ | Dec 31, 2024 | 79d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Mar 28, 2024 | Annual ↗ | Dec 31, 2023 | 88d |
| Nov 8, 2023 | Quarterly ↗ | Sep 30, 2023 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 13, 2026 | Acquisition or disposal ↗ |
| Jun 5, 2026 | Director or officer change · Shareholder vote ↗ |
| May 26, 2026 | Material agreement · Other events ↗ |
| May 22, 2026 | Regulation FD · Other events ↗ |
| May 7, 2026 | Results ↗ |
| Mar 30, 2026 | Director or officer change ↗ |
| Mar 19, 2026 | Results ↗ |
| Dec 8, 2025 | Regulation FD · Other events ↗ |
| Nov 10, 2025 | Results ↗ |
| Aug 11, 2025 | Material agreement · Unregistered share sale · Other events ↗ |
| Aug 8, 2025 | Regulation FD · Other events ↗ |
| Aug 6, 2025 | Results · Other events ↗ |